Through network pharmacology, four ginsenosides related to AD pathogenesis were pre-screened, and Ginsenoside Ro showed good therapeutic efficacy in vitro (Liu et al., 2023a), However, the exact mechanism remains unclear, necessitating further validation of Ginsenoside Ro’s molecular mechanisms in treating AD using APP/PS1 mice. This evidence concerns the gene APP and Alzheimer disease.